Skip to main content
SpringerLink
Log in

Overview of HBV Therapy

  • Chapter
Antiviral Chemotherapy 5

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 458))

  • 208 Accesses

Abstract

The natural history of infection in patients with active HBV viral replication (HBsAg, HBeAg and HBV DNA positive) tends to be progressive, with development of long-term complications such as portal hypertension and hepatic decompensation. As well, the risk of developing hepatocellular carcinoma (HCC) is increased 10 to 390-fold in patients with chronic HBV infection,1 and in regions where HBV is endemic, HCC is the leading cause of cancer related deaths. Evolving therapies, discussed in this chapter, may be changing the natural history of HBV infection and even reducing the risk of HCC development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beasley R, Ling C, Hwang L, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22, 707 men in Taiwan. Lancet 1981; 2: 1129–1133.

    Article  PubMed  CAS  Google Scholar 

  2. Wright T, Lau J. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340–1345.

    Article  PubMed  CAS  Google Scholar 

  3. Niederau C, Heinges T, Lange S, et al. Long-term follow-up of the HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine 1996; 334: 1422–1427.

    Article  PubMed  CAS  Google Scholar 

  4. Lau J, Wright T. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335–1340.

    PubMed  CAS  Google Scholar 

  5. Perrillo R, Schiff E, Davis G, et al. A randomized, controlled trial of interferon alfa-2b alone and after Prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301.

    Article  PubMed  CAS  Google Scholar 

  6. Wong D, Cheung A, O’ Rourke K, Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 1993; 119(4): 312–323.

    CAS  Google Scholar 

  7. Lok A, Lai C, Lau J. Interferon alfa therapy in patients with chronic hepatitis B virus infection. Effects on hepatitis B virus DNA in the liver. Gastroenterology 1991; 100: 756–761.

    PubMed  CAS  Google Scholar 

  8. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm S. Long term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alpha. Hepatology 1997; 26(5): 1338–1342.

    Article  PubMed  CAS  Google Scholar 

  9. Perrillo RP, Tamburron C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908–916.

    Article  PubMed  CAS  Google Scholar 

  10. Villeneuve J, Desrochers M, Infante-Rivard L, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106(1000-5.): 577–580.

    Google Scholar 

  11. Lampertico P, Ninno E, Manzin A, et al. A randomized, controlled trial of a 24 month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26(6): 1621–1625.

    Article  PubMed  CAS  Google Scholar 

  12. Davis G. Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liver Dis 1989; 9(4): 267–272.

    Article  PubMed  CAS  Google Scholar 

  13. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive hepatitis B. Ann Intern Med 1995; 122(9): 664–675.

    PubMed  CAS  Google Scholar 

  14. Dusheiko G, Roberts J. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995; 22(6): 1863–1873.

    PubMed  CAS  Google Scholar 

  15. Ling R, Multimer D, Ahmed M, et al. Selection of mutations in hepatitis B virus Polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711–713.

    Article  PubMed  CAS  Google Scholar 

  16. Lai C, Ching C, Ting A, et al. Lamivudine is effective in suppressing Hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo controlled trial. Hepatology 1997; 25: 241–244.

    Article  PubMed  CAS  Google Scholar 

  17. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333(25): 1657–1661.

    Article  PubMed  CAS  Google Scholar 

  18. Lai C, Chien R, Leung N et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339(2): 61–68.

    Article  PubMed  CAS  Google Scholar 

  19. Dienstag J, Schiff E, Gitlin N, et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24(Suppl 1): 188A.

    Google Scholar 

  20. Bartholomew M, Jansen R, Jeffers L, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20–22.

    Article  PubMed  CAS  Google Scholar 

  21. Main J, Brown J, Howells C, et al. A double-blind, placebo controlled study to assess the effect of famci-clovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3: 211–215.

    Article  PubMed  CAS  Google Scholar 

  22. Trepo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology 1996; 24(4): 188A.

    Google Scholar 

  23. Kruger M, Tillmann H, Trautwein C, et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplantation and Surgery 1996; 2: 253–262.

    Article  PubMed  CAS  Google Scholar 

  24. Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D, et al. Phase I/II study of oral lobucavir in adults with chronic hepatitis B infection. Second International Conference on Therapies for Viral Hepatitis 1997: 2.

    Google Scholar 

  25. DeHertogh D, Colonno R, Grasela D. Lobucavir and BMS-200475: two potent new agents for hepatitis B. Second International Conference of Therapies for Viral Hepatitis 1997.

    Google Scholar 

  26. Gilson R, Chopra K, Murray-Lyon I, et al. A placebo-controlled phase I/II study of Adefovir dipixovil (BIS-POM PMEA) in patients with chronic hepatitis B infection. Hepatology 1996; 24: 620A.

    Article  Google Scholar 

  27. Virani-Ketter N. Adefovir dipivoxil for the treatment of chronic hepatitis B. Second International Conference on Therapies for Viral Hepatitis 1997: 22.

    Google Scholar 

  28. Vitiello A, Ishioka G, Grey H, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95: 341–349.

    Article  PubMed  CAS  Google Scholar 

  29. Heathcote J, McHutchison J, Benner K, et al. CY-1899: a therapeutic vaccine for chronic hepatitis B. Hepatology 1996; 24: 628A.

    Article  Google Scholar 

  30. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216–225.

    PubMed  CAS  Google Scholar 

  31. Locarnini S, Aye T, Shaw T, De Man R, et al. The emergence of famciclovir resistant mutations in the hepatitis B virus Polymerase during therapy in patients following liver transplantation. Hepatology 1997; 26(4): 368A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, California, 94121, USA

    Mario G. Pessoa & Teresa L. Wright

Authors
  1. Mario G. Pessoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teresa L. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Macfarlane Burnet Centre for Medical Research, Fairfield, Victoria, Australia

    John Mills

  2. University of California, San Francisco, San Francisco, California, USA

    Paul A. Volberding

  3. University of Washington, Seattle, Washington, USA

    Lawrence Corey

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pessoa, M.G., Wright, T.L. (1999). Overview of HBV Therapy. In: Mills, J., Volberding, P.A., Corey, L. (eds) Antiviral Chemotherapy 5. Advances in Experimental Medicine and Biology, vol 458. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4743-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4743-3_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7150-2

  • Online ISBN: 978-1-4615-4743-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation